Reuters logo
EU agency recommends Roche drug for type of ovarian cancer
June 27, 2014 / 5:16 AM / 3 years ago

EU agency recommends Roche drug for type of ovarian cancer

ZURICH, June 27 (Reuters) - Roche said on Friday that European regulators had recommended approval of its drug Avastin as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy.

Recommendations for marketing approval by the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

Avastin, which is already approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer, was Roche’s biggest seller last year with sales of 6.25 billion Swiss francs ($7 billion).

$1 = 0.8946 Swiss Francs Reporting by Caroline Copley

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below